NEW ORLEANS — Adicet Bio generated a good deal of buzz last June with a unique, off-the-shelf therapy made from a special type of T cell that induced complete remissions in patients with advanced and aggressive B cell lymphomas. But an update reported Saturday showed patients starting to relapse, which may raise questions about the so-called gamma-delta T cell therapy’s durability.
In an early-stage study, two of six patients, or 33%, have maintained complete remissions for at least six months — a closely watched marker of durability. The patients received single infusions of Adicet’s therapy, called ADI-001, containing 100 million or 300 million cells.
Last June, the complete remission rate for these same patients was 80%, although with short follow-up.
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.
Already have an account? Log in
Already have an account? Log in
About the Author Reprints
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect